Reverse Payments Post Actavis: A Litigation Quagmire?
Document Type
Article
Publication Date
7-2015
Language
en-US
Abstract
For the last decade or so, the FTC has had a bee in its bonnet over “reverse payment settlements.” Such a settlement occurs when a pioneer pharmaceutical firm terminates a patent infringement lawsuit against a generic drug maker by forming an agreement under which the generic enters the market at some later date (still before expiration of the patent) in exchange for a payment from the pioneer.
Recommended Citation
Keith N. Hylton,
Reverse Payments Post Actavis: A Litigation Quagmire?
,
in
CPI Antitrust Chronicle
(2015).
Available at:
https://scholarship.law.bu.edu/faculty_scholarship/2545
